Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

June 01, 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

May 23, 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.